NGNE Stock Price
Neurogene Inc.
NGNE stock price is $23.25 (-2.92% on the day), giving Neurogene Inc. a market cap of $465.26M. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
NGNE Stock Overview
- Price
- $23.25
- Previous close
- $23.95
- Open
- $24.00
- Market cap
- $465.26M
- P/E ratio
- -5.1
- 52-week range
- $15.93 - $43.66
- 1-year price target
- $77.22
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NSD
- MarketXLS Rank
- 38
About Neurogene Inc.
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company is headquartered in New York, New York.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NGNE | $23.25 | -2.9% | 571.53K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |